Viracta Therapeutics, Inc.

As of February 24, 2021, Viracta Therapeutics, Inc. is considered overvalued with a negative price-to-book value and an EV to EBITDA ratio indicating no market confidence in recovery, while its stock has declined 89.93% year-to-date, significantly underperforming the S&P 500.

As of June 9, 2025, the market trend is mildly bearish, indicated by daily moving averages and weekly Bollinger Bands, despite some bullish signals from the MACD and RSI, reflecting overall weakness compared to the S&P 500.

As of March 2022, the management team of Viracta Therapeutics, Inc. includes Non-Executive Independent Chairman Mr. James Young, Directors Dr. Stephen Ketchum and Mr. H. Ward Wolff, and Independent Directors Mr. Steve Carchedi and Mr. Matthew Fust. They guide the company's strategic direction and governance.

Viracta Therapeutics, Inc. is a biopharmaceutical company developing targeted inhibitors for hematologic and solid cancers, classified as a micro-cap with a market cap of $0.69 million and a recent net profit of -$11 million.

As of Jun 18, Viracta Therapeutics, Inc. has a market capitalization of 0.69 million, categorizing it as a Micro Cap company, with net sales of 0.00 million and a net profit of -43.29 million over the latest four quarters. The company's shareholder's funds are 18.32 million, and total assets are 56.69 million as of Dec 23.